Novartis hit on Gleevec in U.S. tells the tale for India's Sun Pharma

Novartis HQ

Novartis ($NVS) held about half its market share as India's Sun Pharmaceuticals launched a generic version of blood cancer drug Gleevec/Glivec (imatinib) in the U.S. at the start of February--but that figure is expected to collapse by the third quarter as the 180-day market exclusivity ends and a swarm of new offers appear.

David Epstein, head of pharma for the Swiss-based firm, discussed the loss of exclusivity in the world's top market at length on a recent earnings call, setting up Mumbai-based Kotak Institutional Equities analysts Chirag Talati and Kumar Gaurav to work backward and crunch a few numbers in relation to Sun's launch.

Epstein noted that the overall pharma division sales were up 1% in the first quarter and would have gained 4% without the loss of exclusivity for the oncology therapy in the U.S.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The analysts noted that Novartis' first-quarter results suggest 35% to 40% price erosion for Gleevec in the U.S., with Novartis retaining over 50% market share so far, according to a note to clients.

"We believe the key sensitivity for Gleevec is the competition it will face after the 180-day exclusivity," the analysts said, adding that by the second half of 2018, "We expect pricing to collapse by 80-90% and face further erosion over time as the market eventually will settle at eight-to-10 players."

Epstein too sees a price collapse--but a little bit quicker.

"There will be multiple generics entering in, if I recall correctly, in Q3 of this year," he said on the call. "It's hard to know exactly how many, but would not be surprising if there were four, 5 or 6 of them. If history is any guide, prices will more or less collapse at that point in time, and you would expect then our volume to become fairly small."

Kotak, placing a sell recommendation on Sun citing the upcoming Gleevec competition and ongoing restructuring, said among the players ready to come in on day 181 are Toronto-based Apotex, using an API from Hyderabad-based Natco Pharma, and Israel's Teva, using an API from Croatia-based unit Pliva.

- here's the Novartis release

Suggested Articles

Glenmark hopes to raise cash from selling drugs outside of its focus therapeutic areas and from finding new investors for its API and innovation spinoffs.

Sun's Shanghvi took a 99% pay cut last year. Dr. Reddy's copies of Copaxone and NuvaRing were rejected by the FDA. Natco eyes China amid hardship.

There are five or six potential deals similar to Takeda's mooted European sale Stada could go after, CEO Peter Goldschmidt said.